CREBBP and acute lymphoblastic leukemia: Moreover, preliminary results from an early phase clinical trial of Venetoclax in relapsed pediatric malignancies (NCT03236857) have highlighted responses in high-risk patients, including the small number of CREBBP-mutated B-ALL patients enrolled, providing supportive evidence that our results will be clinically translatable43.